Different Safety Profile of Risperidone and Paliperidone Extended-release
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The main objective of this study was to assess subjective experiences related to secondary
negative symptoms and cognitive performance in healthy volunteers in response to multiple
doses of paliperidone ER and risperidone in a double-blind, placebo-controlled trial. Adverse
events caused by these drugs were also evaluated.
Phase:
Phase 4
Details
Lead Sponsor:
Chonbuk National University Hospital
Collaborators:
AstraZeneca Janssen Korea, Ltd., Korea Korea Otsuka Pharmaceutical Co., Ltd. Sanofi-Synthelabo